The DOI matches its Crossref record.
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study
Abstract
Summary: We evaluated whether a postoperative regimen with melagatran followed by oral ximelagatran, two new direct thrombin inhibitors, was an optimal regimen for thromboprophylaxis in major orthopaedic surgery. In a double-blind study, 2788 patients undergoing total hip or knee replacement were randomly assigned to receive for 8 to 11 days either 3 mg of subcutaneous melagatran started 4-12 h postoperatively, followed by 24 mg of oral ximelagatran twice-daily or 40 mg of subcutaneous enoxaparin once-daily, started 12 h preoperatively. Ximelagatran was to be initiated within the first two postoperative days. The primary efficacy endpoint was venous thromboembolism (deep-vein thrombosis detected by mandatory venography, pulmonary embolism or unexplained death). The main safety endpoint was bleeding. Venous thromboembolism occurred in 355/1146 (31.0%) and 306/1122 (27.3%) patients in the ximelagatran and enoxaparin group, respectively, a difference in risk of 3.7% in favour of enoxaparin (p = 0.053). Bleeding was comparable between the two groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Self-citationEriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationERIKSSON, B. I., DAHL, O. E., ROSENCHER, N., KURTH, A. A., VAN DIJK, C. N., FROSTICK, S. P., KÄLEBO, P., CHRISTIANSEN, A. V., HANTEL, S., HETTIARACHCHI, R., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02748.x · Cited by 979
Self-citationDi Nisio, M., Middeldorp, S., & Büller, H. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044440 · Cited by 655
Metadata
- Authors
- Agnelli, G., Cohen, A., Dahl, O., Mouret, P., Rosencher, N., Eskilson, C., Nylander, I., Frison, L., ögren, M., Eriksson, B., & on behalf of the METHRO III Study Group* (* see Appendix for METHRO III study participants)
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2003
- Volume
- 89
- Issue
- 02
- Pages
- 288-296
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1860102466
- Cited by
- 252
- References
- 0
- FWCI
- 31.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. https://app.cochat.ai/papers/10.1055/s-0037-1613445
- The paper
- Agnelli, G., Cohen, A., Dahl, O., Mouret, P., Rosencher, N., Eskilson, C., Nylander, I., Frison, L., ögren, M., Eriksson, B., & on behalf of the METHRO III Study Group* (* see Appendix for METHRO III study participants). (2003). Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0037-1613445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.